RARS1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: RARS1

NCBI ID: G5917

RARS1

RARS1: A Potential Drug Target and Biomarker for Various Diseases

RARS1 (HLD9) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. RARS1 is a key regulator of gene expression in many cell types and is involved in the regulation of various cellular processes, including cell growth, differentiation, and inflammation.

Diseases and Their association with RARS1

RARS1 has been associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Cancer

RARS1 has been shown to play a role in the regulation of cancer cell growth and progression. Several studies have shown that RARS1 is highly expressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. Additionally, research has shown that inhibiting RARS1 can lead to the growth inhibition of cancer cells and a reduction in their ability to migrate and survive in the presence of chemotherapy drugs.

Neurodegenerative diseases

RARS1 has also been associated with the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Research has shown that RARS1 is involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of cellular stress and inflammation. Additionally, studies have shown that RARS1 is expressed in the brains of individuals with neurodegenerative diseases and that inhibiting RARS1 may be a potential therapeutic approach for these diseases.

Autoimmune disorders

RARS1 has also been associated with the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Research has shown that RARS1 is involved in the regulation of immune cell function and that it can contribute to the development of autoimmune disorders. Additionally, studies have shown that inhibiting RARS1 has the potential to reduce the expression of autoimmune genes and improve the regulation of immune cell function.

Potential Therapeutic Applications

Given the association of RARS1 with the development and progression of various diseases, there is significant potential for RARS1 to be targeted as a drug or biomarker for therapeutic intervention.

Drug Targeting

One potential approach to targeting RARS1 is to use small molecules or drugs that can inhibit its activity. Research has shown that inhibitors of RARS1 have the potential to inhibit the growth of cancer cells and reduce the production of neurotransmitters that contribute to neurodegenerative diseases. Additionally, inhibitors of RARS1 have the potential to reduce inflammation and improve the regulation of immune cell function, which may be useful for treating autoimmune disorders.

Biomarker

Another potential approach to targeting RARS1 is to use biomarkers that can be used to monitor disease progression or the effectiveness of therapeutic interventions. Research has shown that RARS1 is involved in the regulation of gene expression and that its expression can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, the level of RARS1 expression can be used as a biomarker for tracking the effectiveness of therapeutic interventions, such as cancer chemotherapy drugs.

Conclusion

In conclusion, RARS1 (HLD9) is a non-coding RNA molecule that has been associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Given its potential as a drug target and biomarker, there is significant potential for RARS1 to be used as a therapeutic intervention for a variety of diseases. Further research is needed to fully understand the role of RARS1 in disease and to develop safe and effective therapeutic approaches that can harness its potential.

Protein Name: Arginyl-tRNA Synthetase 1

Functions: Forms part of a macromolecular complex that catalyzes the attachment of specific amino acids to cognate tRNAs during protein synthesis (PubMed:25288775). Modulates the secretion of AIMP1 and may be involved in generation of the inflammatory cytokine EMAP2 from AIMP1 (PubMed:17443684)

The "RARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets